Xin Lang Cai Jing·2025-09-09 02:16Group 1 - The core viewpoint of the news is that BeiGene's stock has seen a significant increase, with a rise of 5.03% to 334.00 CNY per share, and a total market capitalization of 514.31 billion CNY [1] - BeiGene, established on October 28, 2010, and listed on December 15, 2021, focuses on the research, development, production, and commercialization of innovative drugs, with 99.19% of its revenue coming from oncology drugs [1] - The trading volume for BeiGene reached 1.313 billion CNY, with a turnover rate of 3.44% [1] Group 2 - According to data from the top ten holdings of funds, one fund under Xinda Australia has a significant position in BeiGene, holding 600 shares, which accounts for 0.12% of the fund's net value [2] - The fund, Xin Ao New Target Flexible Allocation Mixed A (003456), has a total scale of 3.261 million CNY and has achieved a year-to-date return of 2.73% [2] - The fund manager, Yang Bin, has been in position for 2 years and 311 days, with the fund's total assets amounting to 12.179 billion CNY [2]